Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-991: Pembrolizumab Plus Enzalutamide Plus ADT in mHSPC
NCT04191096Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in prostate cancer (PCa), sponsored by Merck & Co. Primary endpoints: Radiographic Progression-free Survival at 32 months and Overall Survival at 32 months. Started Feb 2020; status: terminated.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04191096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191096.